Collaboration to empower gene therapy, OBiO Technology and Medicilon reach a strategic collaboration

On September 20, 2022, OBiO Technology (OBiO) and Shanghai Medicilon Inc. (Medicilon) held a signing ceremony of strategic collaboration in the field of gene and cell therapy services.  The two parties will work together to empower clients with their respective professional technologies, jointly accelerate the development of gene and cell therapy drugs, and promote the early benefit of advanced therapies to patients.

During the collaboration, OBiO and Medicilon complement their resources to jointly provide clients with professional services with better experience and higher efficiency.

The two parties will adhere to the principle of "resource sharing, efficiency and pragmatism, and win-win cooperation" to reach a long-term strategic partnership.  The two parties will integrate pre-clinical CMC pharmaceutical research, drug efficacy, pharmacokinetics and GLP safety evaluation service capabilities, and use the efficient project management communication mechanism to jointly provide clients with comprehensive, high-quality, efficient and rapid new drug development and production services.  In addition, OBiO and Medicilon will also collaborate closely in the discovery of innovative gene therapy vectors to discover and create better gene therapy vectors and promote the development of the industry.